全文获取类型
收费全文 | 580005篇 |
免费 | 42783篇 |
国内免费 | 15321篇 |
专业分类
耳鼻咽喉 | 5613篇 |
儿科学 | 13478篇 |
妇产科学 | 8845篇 |
基础医学 | 54598篇 |
口腔科学 | 11750篇 |
临床医学 | 61410篇 |
内科学 | 70267篇 |
皮肤病学 | 7047篇 |
神经病学 | 29871篇 |
特种医学 | 12386篇 |
外国民族医学 | 58篇 |
外科学 | 53173篇 |
综合类 | 98183篇 |
现状与发展 | 30篇 |
一般理论 | 59篇 |
预防医学 | 52749篇 |
眼科学 | 9826篇 |
药学 | 59242篇 |
594篇 | |
中国医学 | 58872篇 |
肿瘤学 | 30058篇 |
出版年
2023年 | 8603篇 |
2022年 | 13882篇 |
2021年 | 22739篇 |
2020年 | 21142篇 |
2019年 | 25428篇 |
2018年 | 22974篇 |
2017年 | 20884篇 |
2016年 | 19142篇 |
2015年 | 18445篇 |
2014年 | 37142篇 |
2013年 | 38410篇 |
2012年 | 34031篇 |
2011年 | 36551篇 |
2010年 | 29800篇 |
2009年 | 26532篇 |
2008年 | 25291篇 |
2007年 | 26878篇 |
2006年 | 23549篇 |
2005年 | 21190篇 |
2004年 | 17623篇 |
2003年 | 15478篇 |
2002年 | 11920篇 |
2001年 | 11105篇 |
2000年 | 9144篇 |
1999年 | 7967篇 |
1998年 | 6107篇 |
1997年 | 5724篇 |
1996年 | 5248篇 |
1995年 | 4961篇 |
1994年 | 4583篇 |
1993年 | 3801篇 |
1992年 | 3564篇 |
1991年 | 3144篇 |
1990年 | 2709篇 |
1989年 | 2468篇 |
1988年 | 2318篇 |
1987年 | 1935篇 |
1986年 | 1664篇 |
1985年 | 4538篇 |
1984年 | 5581篇 |
1983年 | 3871篇 |
1982年 | 4423篇 |
1981年 | 4102篇 |
1980年 | 3604篇 |
1979年 | 3328篇 |
1978年 | 2868篇 |
1977年 | 2195篇 |
1976年 | 2486篇 |
1975年 | 1857篇 |
1974年 | 1611篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
31.
32.
Discrimination towards individuals with disabilities is problematic within nursing. There have been calls to increase diversity in nursing and this includes embracing nurses with disabilities. Increasing diversity in nursing requires increasing diversity among nursing students; in this way, nurse educators are gatekeepers to the profession. Clinical education is a crucial element of nursing education, yet there have been very few studies related to the clinical education of nursing students with disabilities. There have been no studies of attitudes of acute care nurse preceptors toward students with disabilities in the United States. This gap is important as the majority of clinical experiences occur in the acute care environment. Utilizing a focused ethnography, semi-structured interviews were conducted with 20 acute care nurses with at least two years’ experience precepting students. While positive feelings about nursing students with disabilities were shared, thoughts and behavioral intentions remained negative. Six themes emerged: safety, barriers, otherness, communicating to meet needs, disclosure, and student versus colleague. Attitudinal barriers are the primary barriers faced by individuals with disabilities in becoming and practicing as nurses. Nurses in practice and education must embrace more inclusive attitudes towards individuals with disabilities. 相似文献
33.
AimThe aim of the study was to describe the characteristics of the Bachelor’s thesis of fourth-year nursing students at a Spanish public university, the criteria that students used to choose a topic and students’ degree of satisfaction after completing the Bachelor’s thesis.DesignQuantitative study.MethodsWe examined 420 Bachelor’s theses carried out from 2013 to 2018 and conducted an online survey among fourth-year students in the 2017–18 and 2018–19 academic years (81 completed questionnaires).ResultsThe Bachelor’s thesis took the form of a research proposal. The most frequent proposal type was a qualitative hospital-based study whose objective was to understand the experiences of adult or adolescent patients, close family members, or nurses. Students chose topics for personal reasons. Most participants reported feeling satisfied with the knowledge and skills acquired.ConclusionsStudents completing a Bachelor’s thesis in the form of a research proposal have the potential to transfer their research skills to their nursing practice. 相似文献
34.
BackgroundTraditional Chinese medicine (TCM) has been proven to played a great important role on the treatment of COVID-19. As one of the drugs recommended in Chinese guidelines, Lianhua Qingwen Granules or Capsules (LQ) are widely used.This systematic review and meta-analysis amis to evaluate the clinical efficacy of LQ on the treatment of COVID-19.MethodsSeven databases (PubMed, EMBASE, CENTRAL, CNKI, VIP, CBM and Wanfang) were searched to include all appropriate clinical trials that explore the efficacy of LQ on the treatment of COVID-19.ResultA total of 3 trials including 245 COVID-19 patients were eventually enrolled.Compared with the control group,the LQ group showed great significant difference on reducing the rate of clinical change to severe or critical condition[RR = 0.38, 95 %CI (0.17,0.85), P < 0.05]and the fever time (SMD =-0.57,95 %CI (-0.96,-0.17), P<0.05),as well as the significant improvement on the disappearance rate of the clinical symptoms: fever [RR = 1.36,95 %CI (1.14,1.61), P < 0.05],cough[RR = 1.99,95 %CI (1.39,2.86), P < 0.05],fatigue[RR = 1.52,95 %CI (1.15,2.01), P < 0.05] and anhelation [RR = 4.18,95 %CI (1.99,8.81), P < 0.05], but no significance on expectoration[RR = 2.46,95 %CI (0.81,7.51), P < 0.05].ConclusionThe clinical application of LQ on the treatment of COVID-19 has significant efficacy in improving clinical symptoms and reducing the rate of clinical change to severe or critical condition. Nevertheless, due to the limited quantity and quality of the included studies, more and higher quality trials with more observational indicators are expected to be published. 相似文献
35.
36.
37.
Heather L. Brown 《Journal of emergency nursing》2021,47(2):321-325
The coronavirus 2019 pandemic has affected almost every aspect of health care delivery in the United States, and the emergency medicine system has been hit particularly hard while dealing with this public health crisis. In an unprecedented time in our history, medical systems and clinicians have been asked to be creative, flexible, and innovative, all while continuing to uphold the important standards in the US health care system. To continue providing quality services to patients during this extraordinary time, care providers, organizations, administrators, and insurers have needed to alter longstanding models and procedures to respond to the dynamics of a pandemic. The Emergency Medicine Treatment and Active Labor Act of 1986, or EMTALA, is 1 example of where these alterations have allowed health care facilities and clinicians to continue their work of caring for patients while protecting both the patients and the clinicians themselves from infectious exposures at the same time. 相似文献
38.
39.
《Vaccine》2021,39(42):6333-6339
Px563L is a next-generation anthrax vaccine candidate consisting of a protein subunit, mutant recombinant protective antigen SNKE167-ΔFF-315-E308D (mrPA), and liposome-embedded monophosphoryl lipid A (MPLA) adjuvant. Px563L has the potential to deliver an improved safety and immunogenicity profile relative to the currently licensed vaccine, which is produced from filtered B. anthracis culture supernatants.We conducted a Phase 1, double–blind, placebo–controlled, dose–escalation study in 54 healthy subjects to evaluate Px563L at 3 dose levels of mrPA (10, 50, and 80 mcg). For each dose level, 18 subjects were randomized in an 8:8:2 ratio to Px563L (mrPA with adjuvant), RPA563 (mrPA only) or placebo (saline). Each subject received an intramuscular (IM) injection on Day 0 and Day 28. Primary safety and immunogenicity analysis was conducted after all subjects completed the Day 70 visit, a duration deemed clinically relevant for post-exposure prophylaxis. Long-term safety was assessed through Day 393.Vaccinations with Px563L at all dose levels were well-tolerated. There were no serious adverse events or adverse events (AE) leading to early withdrawal. In all treatment groups, most AEs were due to injection site reactions, and all AEs at the 10 and 50 mcg dose levels were mild. For the primary immunogenicity endpoint (protective toxin neutralizing antibody 50% neutralization factor [TNA NF50]), titers started to increase significantly after the second administration of Px563L, from Day 35 through Day 70, with the geometric mean and lower bound of the 95% confidence interval exceeding 0.56, a threshold correlating with significant survival in animal models of anthrax exposure.In conclusion, Px563L, administered as two IM doses 28 days apart, was well-tolerated and elicited a protective antibody response starting at seven days after the second vaccination. These findings support the continued development of Px563L in a two-dose regimen for anthrax post-exposure prophylaxis. ClinicalTrials.gov identifier NCT02655549. 相似文献
40.